Prolonium | 45021-15-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Prolonium
• 英文别名: [2-hydroxy-3-(trimethylazaniumyl)propyl]-trimethylazanium
• CAS: 45021-15-6
• 化学式: C9H24N2O+2
• 分子量: 176.3
• InChiKey: SEOAESNTVSJYIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• POLYCATIONIC ORGANIC COMPOUNDS
  申请人：Little Charles

  公开号：US20100081844A1

  公开（公告）日：2010-04-01

  A chemical compound having the general formula (I): wherein: each group R 1 , R 2 , R 3 , R′ 1 , R′ 2 , and R′ 3 is alkyl, aryl, or aralkyl; each R 4 , R′ 4 , R 5 and R′ 5 is alkyl, aryl, aralkyl or —(CH 2 ) a —(CHY) b —(CH 2 ) c —N + R 1 R 2 R 3 An − ; each Y is —H, —OH, —OR 6 , halo, alkyl, aryl or aralkyl, wherein -R 6 may be alkyl or —(CH 2 ) a —(CHOH) b —(CH 2 ) c —N + R 1 R 2 R 3 An − , and at least one Y is other than —OH or —OR 6 ; each q and z is from 0 to about 6, and q+z is 1 to about 6; each a, b, and c is from 0 to 2, and a+b+c in any fragment is from 3 to 6; and each An − independently may be one or more or a mixture of organic or inorganic, monovalent or polyvalent anion as needed to obtain a neutral compound.

  一种具有通式（I）的化学化合物，其中：每个基团R1、R2、R3、R′1、R′2和R′3均为烷基、芳基或芳基烷基；每个R4、R′4、R5和R′5均为烷基、芳基、芳基烷基或—（CH2）a—（CHY）b—（CH2）c—N+R1R2R3An−；每个Y为—H、—OH、—OR6、卤素、烷基、芳基或芳基烷基，其中-R6可以是烷基或—（CH2）a—（CHOH）b—（CH2）c—N+R1R2R3An−，并且至少一个Y不是—OH或—OR6；每个q和z为0至约6，q+z为1至约6；每个a、b和c为0至2，在任何片段中a+b+c为3至6；并且每个An−独立地可以是一个或多个有机或无机、一价或多价阴离子的混合物，以便获得中性化合物。
• Kosmetisches Mittel, enthaltend (C8 bis C20)-Alkane, Dimethylpolysiloxan, Dimethiconol und mindestens einen festigenden Wirkstoff
  申请人：Henkel AG&Co. KGAA

  公开号：EP2626062A2

  公开（公告）日：2013-08-14

  Kosmetische Mittel zur kosmetischen Behandlung keratinhaltiger Fasern, insbesondere menschlicher Haare, enthaltend in einem kosmetisch akzeptablen Träger (a) eine Mischung aus i) mindestens einem (C8 bis C20)-Alkan ii) mindestens einem bei 20°C und 1013 mbar flüssigen Polydimethylsiloxan und iii) mindestens einem Dimethiconol, und (b) mindestens einen haarkosmetischen Wirkstoff ausgewählt aus mindestens einem Wirkstoff der Gruppe, die gebildet wird aus festigenden Wirkstoffen, quaternären Ammoniumverbindungen und Tensiden,

  用于含角蛋白纤维（尤其是人类头发）美容处理的化妆品组合物，在化妆品可接受的载体中含有 (a) 以下物质的混合物 i) 至少一种（C8 至 C20）烷烃 至少一种聚二甲基硅氧烷，在 20°C 和 1013 毫巴条件下呈液态；以及 至少一种二甲基硅氧烷醇，以及 (b) 至少一种头发化妆品活性成分，该活性成分选自由紧致活性成分、季铵化 合物和表面活性剂组成的组中的至少一种活性成分、
• Methods of enhancing and generating microfractures in shale formations
  申请人：Halliburton Energy Services, Inc.

  公开号：US10053618B2

  公开（公告）日：2018-08-21

  Methods for treating a shale formation may include injecting a pad fluid including a shale stabilizing agent into a shale formation to generate one or more fractures. The method may also include injecting a fracturing slurry including proppant particulates into the one or more generated fractures such that the proppant particulates form microfractures along shale fracture faces. At least a portion of the proppant particulates may be at least partially coated with at least one oxidizing agent.

  处理页岩层的方法可包括将包括页岩稳定剂的垫层流体注入页岩层，以产生一条或多条裂缝。该方法还可包括将包括支撑剂颗粒的压裂浆液注入一个或多个生成的裂缝中，使支撑剂颗粒沿页岩裂缝面形成微裂缝。支撑剂颗粒的至少一部分可以至少部分涂覆一种氧化剂。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。